Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus ULTRAVIST 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus ULTRAVIST 370.
DIATRIZOATE MEGLUMINE vs ULTRAVIST 370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate meglumine is an ionic, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, thereby enhancing radiographic imaging. It does not exert pharmacological effects via receptor interaction but functions by attenuating X-ray beams, providing contrast between vascular structures and surrounding tissues.
Iodinated non-ionic contrast agent that attenuates X-rays due to its high iodine content (370 mg I/mL), enhancing vascular and tissue contrast during imaging. Does not bind to plasma proteins and has minimal pharmacological effects.
Intravenous: 1-2 mL/kg (305-610 mg I/kg) of 60% or 76% solution for urography; 40-60 mL of 50% solution for retrograde cystourethrography. Oral: 200-600 mL of 4.8% suspension for GI contrast.
Adult: IV administration of 370 mg iodine/mL at 1-1.5 mL/kg (370-555 mg I/kg) for CT; up to 300 mL total. Rate: 1-5 mL/sec.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function (CLcr >90 mL/min). Half-life is significantly prolonged in renal impairment (up to 20-40 hours in anuria), necessitating dose adjustment and caution.
Terminal elimination half-life: 2 hours (normal renal function); prolonged to up to 36 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion via glomerular filtration; >95% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary elimination.
Renal: 95% unchanged within 24 hours via glomerular filtration; Biliary/Fecal: <5%; negligible biliary excretion.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent